| Serial Number | 97361222 |
| Word Mark | OXFORD BIOMEDICA SOLUTIONS |
| Filing Date | Wednesday, April 13, 2022 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, December 26, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 31, 2023 |
| Goods and Services | Custom manufacture of products relating to biotechnology; manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; manufacture of biotechnology products; manufacture of viral and non-viral vectors; manufacture of vaccines |
| Goods and Services | Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases, vaccines; pharmaceutical substances and preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; gene therapy products, namely, nanoparticles, viral vectors, retroviral vectors, lentiviral vectors and non-viral vectors for the delivery of genes to cells, all for medical purposes; vaccine manufacturing preparations; viral vaccines, namely, viral vector, retroviral vector, lentiviral vector and non-viral vector preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; biochemical and chemical products for use in medical science, namely, viral vectors; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes |
| Goods and Services | Preparation and review of reports for regulatory approval of pharmaceuticals and bioceuticals; licensing of intellectual property; regulatory compliance consulting in the field of chemistry manufacturing and controls (CMC) activities |
| Goods and Services | Medical diagnostic testing; information relating to pharmaceuticals, bioceuticals and advanced therapy medicinal products; providing medical information to medical professionals in the form of reports in the field of biotechnology, gene therapy and cell therapy; consultancy, advice and information in the field of clinical trials, healthcare, pharmaceuticals and advanced therapy medicinal products; medical advisory services relating to vaccination regimes; medical advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders, and pharmaceutical and biochemical preparations for contraceptive purposes, in humans and animals |
| NOT AVAILABLE | "OXFORD" AND "SOLUTIONS" |
| Goods and Services | Scientific research and development services in the field of biochemistry and genetic engineering; biochemistry engineering; genetic engineering; design of manufacturing facilities; quality control for others; scientific and technological services, namely, testing and validation services in the fields of gene and cell therapy and biotechnology; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; medical and scientific laboratory services; scientific and technological services, namely, scientific research, development and analysis in the fields of gene and cell therapy and biotechnology; industrial analysis services, namely, analysis of viral vectors and gene therapy products to assure compliance with medical and pharmaceutical industry standards; provision of scientific information in the field of biotechnology, gene therapy and cell therapy; research and scientific analysis relating to drug discovery and development for others; scientific research in the nature of conducting clinical trials for others; manufacture of viral vectors, gene therapy and cell therapy products; product and manufacturing process development in the fields of biotechnology, gene therapy and cell therapy |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 19, 2022 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 19, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 19, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 19, 2022 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 19, 2022 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Oxford BioMedica Plc |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 11 - Company |
| Address | Oxford OX46LT GB |
| Party Name | Oxford BioMedica Plc |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 11 - Company |
| Address | Oxford OX46LT GB |
| Event Date | Event Description |
| Saturday, April 16, 2022 | NEW APPLICATION ENTERED |
| Tuesday, April 19, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, January 31, 2023 | ASSIGNED TO EXAMINER |
| Friday, February 3, 2023 | NON-FINAL ACTION WRITTEN |
| Friday, February 3, 2023 | NON-FINAL ACTION E-MAILED |
| Friday, February 3, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, April 28, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, September 14, 2023 | ASSIGNED TO LIE |
| Thursday, September 14, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, September 14, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, September 20, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, October 11, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 31, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 31, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 26, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Monday, June 24, 2024 | TEAS DELETE 1(B) BASIS RECEIVED |